Cell type-associated traits map for the [Lake_2017_VisualCortex_Oligodendrocyte][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [Lake_2017_VisualCortex_Oligodendrocyte]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 5.00e-2 | 5.41e-3 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 5.00e-2 | 6.43e-3 |
BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 5.00e-2 | 1.08e-2 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-3 | 5.49e-6 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-4 | 4.03e-4 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-5 | 2.38e-3 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 2.32e-2 |
Cerebral White Matter Hyperintensity | Cerebral White Matter Hyperintensity | MTC | Traylor | 2016 | NA | 3670 | 5.00e-2 | 5.90e-3 |
Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 5.00e-2 | 1.31e-3 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 5.00e-2 | 3.36e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-3 | 8.39e-3 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-5 | 2.36e-2 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 5.00e-2 | 3.08e-2 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 1.11e-2 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 5.00e-2 | 1.11e-2 |
Gait Speed | Gait Speed | MTC | Ben-Avraham | 2017 | NA | 31478 | 5.00e-2 | 3.37e-2 |
Gait Speed | Gait Speed | MTC | Ben-Avraham | 2017 | NA | 31478 | 1.00e-2 | 3.62e-2 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 1.00e-3 | 3.12e-2 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 1.00e-4 | 1.59e-2 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 5.00e-2 | 1.71e-2 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-2 | 2.45e-2 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-3 | 9.27e-4 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-4 | 2.55e-2 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-5 | 1.45e-2 |
Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 5.00e-2 | 3.83e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 5.00e-2 | 1.28e-4 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-2 | 1.16e-3 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-3 | 4.66e-3 |
Partial Epilepsy | Partial Epilepsy | MTC | Kasperaviciute | 2010 | 3445 | 6935 | 5.00e-2 | 2.56e-2 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 8.90e-3 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-3 | 4.64e-2 |
Sleep Duration BMI Adjusted | Sleep Duration BMI Adjusted | MTC | Marinelli | 2016 | NA | 10554 | 5.00e-2 | 3.88e-2 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 5.00e-2 | 2.87e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 1.00e-2 | 3.81e-2 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 2.62e-2 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 1.00e-3 | 1.78e-2 |
Alcohol Consumption | Alcohol Consumption Men Continuous | MTC | Schumann | 2016 | NA | 27560 | 5.00e-2 | 1.28e-2 |
Alcohol Consumption | Alcohol Consumption Men Continuous | MTC | Schumann | 2016 | NA | 27560 | 1.00e-2 | 7.08e-4 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 1.00e-2 | 3.23e-2 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 1.00e-3 | 2.58e-2 |
Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 2.52e-2 |
Anthropometric Extremes | Extreme BMI | MTC | Berndt | 2013 | 7962 | 8106 | 5.00e-2 | 3.97e-3 |
Anthropometric Extremes | Extreme BMI | MTC | Berndt | 2013 | 7962 | 8106 | 1.00e-3 | 2.03e-2 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 5.00e-2 | 1.43e-2 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 1.00e-3 | 1.18e-2 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 1.00e-4 | 3.05e-2 |
Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 5.00e-2 | 2.44e-2 |
Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-4 | 4.06e-2 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 5.00e-2 | 1.14e-3 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-2 | 1.18e-2 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-3 | 3.34e-2 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-4 | 3.55e-4 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-5 | 8.44e-4 |
Anthropometrics Sex Stratified | Hip Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34942 | 5.00e-2 | 4.48e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 5.00e-2 | 2.98e-3 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-2 | 7.89e-5 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-3 | 1.82e-2 |
Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-2 | 3.99e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 4.71e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-2 | 2.87e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-2 | 8.34e-3 |
Anxiety | Anxiety Dichotomous | MTC | Otowa | 2016 | 7016 | 14745 | 5.00e-2 | 3.42e-2 |
Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 5.00e-2 | 3.31e-2 |
Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 1.00e-2 | 5.40e-3 |
Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 5.00e-2 | 6.62e-3 |
Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 5.00e-2 | 8.28e-5 |
Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-2 | 1.73e-2 |
Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 3.04e-2 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 1.69e-2 |
Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.82e-2 |
Blood Cells | Red Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 3.53e-2 |
Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 5.00e-2 | 3.12e-2 |
Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 1.00e-3 | 2.16e-2 |
Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 3.56e-2 |
Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 8.07e-3 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 5.93e-3 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 5.50e-3 |
BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 2.92e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.44e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 2.26e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.67e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 2.15e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 4.37e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 3.50e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 1.08e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.28e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 8.07e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.02e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.77e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.93e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.31e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 8.92e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 7.45e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-5 | 4.00e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 7.21e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 1.55e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 6.44e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.68e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 9.80e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 4.01e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.28e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 5.06e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 4.50e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.66e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 2.21e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.30e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-5 | 2.15e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 2.20e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 4.31e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 32961 | 5.00e-2 | 2.27e-3 |
Bone Mineral Density | Femoral Neck Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 32961 | 1.00e-2 | 4.70e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 15 to 30 | MTC | Medina-Gomez | 2018 | NA | 4180 | 1.00e-2 | 4.84e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 5.00e-2 | 7.08e-4 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 5.00e-2 | 9.68e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-3 | 2.01e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 5.00e-2 | 1.58e-3 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 3.05e-4 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-2 | 2.48e-5 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-3 | 1.50e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-4 | 2.18e-3 |
Cognitive Functions | Memory | MTC | Davies | 2016 | NA | 112067 | 5.00e-2 | 1.92e-2 |
Cognitive Functions | Reaction Time | MTC | Davies | 2016 | NA | 111483 | 5.00e-2 | 3.14e-2 |
Cognitive Functions | Reaction Time | MTC | Davies | 2016 | NA | 111483 | 1.00e-2 | 3.83e-2 |
Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 1.00e-3 | 3.47e-2 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 5.00e-2 | 2.02e-2 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 7.96e-4 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-3 | 1.07e-2 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-5 | 2.54e-2 |
Coronary Artery Disease | Coronary Artery Disease Recessive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 5.00e-2 | 4.62e-4 |
Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 5.00e-2 | 3.48e-2 |
Diarrhoeal Disease | Diarrhea Age 1 | MTC | Bustamante | 2016 | 2693 | 3065 | 5.00e-2 | 2.10e-2 |
Diarrhoeal Disease | Diarrhea Age 2 | MTC | Bustamante | 2016 | 2855 | 2753 | 5.00e-2 | 1.38e-2 |
Diarrhoeal Disease | Diarrhea Age 2 | MTC | Bustamante | 2016 | 2855 | 2753 | 1.00e-2 | 4.54e-4 |
Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 1 | MTC | Bustamante | 2016 | 1339 | 5064 | 5.00e-2 | 1.48e-3 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 5.00e-2 | 3.38e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight Women | MTC | Chu | 2017 | NA | 3684 | 1.00e-2 | 2.26e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 3684 | 5.00e-2 | 4.92e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Women | MTC | Chu | 2017 | NA | 5699 | 5.00e-2 | 3.61e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Women | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 4.00e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Women | MTC | Chu | 2017 | NA | 5699 | 1.00e-3 | 7.21e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14780 | 5.00e-2 | 1.05e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7381 | 5.00e-2 | 4.67e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 5.00e-2 | 5.82e-4 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 1.00e-2 | 1.93e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 3.54e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 7.13e-3 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-2 | 6.23e-3 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-3 | 2.10e-2 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-4 | 2.91e-2 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-5 | 4.03e-2 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 2.67e-2 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 4.11e-2 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-3 | 1.66e-2 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 1.36e-2 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 4.98e-3 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-3 | 2.86e-2 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease | ETC | Pattaro | 2016 | 12385 | 104780 | 5.00e-2 | 7.70e-3 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 5.00e-2 | 3.60e-3 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 1.00e-2 | 4.50e-3 |
Estimated Glomerular Filtration Rate | Serum Creatinine | MTC | Pattaro | 2016 | NA | 133413 | 5.00e-2 | 3.27e-2 |
Estimated Glomerular Filtration Rate | Serum Creatinine | MTC | Pattaro | 2016 | NA | 133413 | 1.00e-2 | 1.09e-2 |
Facial Shape | Mod21 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.07e-2 |
Facial Shape | Mod35 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.27e-2 |
Facial Shape | Mod40 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.66e-3 |
Facial Shape | Mod40 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.18e-4 |
Facial Shape | Mod43 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.18e-3 |
Facial Shape | Mod43 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 5.00e-4 |
Facial Shape | Mod44 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.83e-2 |
Facial Shape | Mod49 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.59e-2 |
Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.44e-2 |
Facial Shape | Mod55 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.58e-2 |
Facial Shape | Mod55 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.17e-2 |
Facial Shape | Mod61 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.89e-2 |
Facial Shape | Mod63 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.30e-2 |
Gestational Weight Gain | Total Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 10555 | 1.00e-2 | 2.87e-2 |
Glucose Stimulated Insulin Secretion | Incremental Insulin At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 2.91e-2 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes Corrected For BMI | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 2.77e-2 |
Glycemic Traits BMI Corrected | Fasting Glucose | MTC | Manning | 2012 | NA | 58074 | 5.00e-2 | 7.50e-3 |
Glycemic Traits BMI Corrected | Fasting Insulin | MTC | Manning | 2012 | NA | 51750 | 5.00e-2 | 4.96e-4 |
Glycemic Traits | Fasting Insulin | ETC | Dupuis | 2010 | NA | 38238 | 5.00e-2 | 2.51e-3 |
Glycemic Traits | Fasting Insulin | ETC | Dupuis | 2010 | NA | 38238 | 1.00e-2 | 1.22e-2 |
Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-2 | 5.88e-3 |
Glycemic Traits | HOMA IR | MTC | Dupuis | 2010 | NA | 37037 | 5.00e-2 | 1.06e-2 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 1.80e-2 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-4 | 1.44e-2 |
Insulin Secretion | Disposition Index Adjusted For BMI | MTC | Wood | 2017 | NA | 2042 | 1.00e-2 | 4.53e-2 |
Insulin Secretion | Insulin Secretion Rate | MTC | Wood | 2017 | NA | 527 | 5.00e-2 | 6.72e-4 |
Insulin Secretion | Insulin Secretion Rate | MTC | Wood | 2017 | NA | 527 | 1.00e-2 | 3.62e-4 |
Insulin Secretion | Insulin Secretion Rate Adjusted For BMI | MTC | Wood | 2017 | NA | 527 | 5.00e-2 | 1.26e-2 |
Insulin Secretion | Insulin Secretion Rate Adjusted For BMI | MTC | Wood | 2017 | NA | 527 | 1.00e-2 | 9.46e-4 |
Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 2.60e-2 |
Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 4.95e-2 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 5.00e-2 | 2.07e-3 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 1.00e-2 | 3.14e-2 |
Kidney Function | CKDi | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 2.07e-2 |
Kidney Function | CKDi | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 6.45e-4 |
Kidney Function | CKDi | MTC | Gorski | 2015 | NA | 45530 | 1.00e-3 | 2.30e-2 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 4.90e-2 |
Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 3.36e-2 |
Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 3.92e-2 |
Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-2 | 2.75e-2 |
Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 3.37e-2 |
Loneliness | Case Control | MTC | Gao | 2017 | 1632 | 3164 | 5.00e-2 | 3.66e-2 |
Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 5.00e-2 | 7.94e-3 |
Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 1.00e-3 | 4.37e-2 |
Longevity | Age 90 Or Greater | MTC | Deelen | 2014 | 5406 | 15112 | 5.00e-2 | 2.19e-2 |
Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.17e-2 |
TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 6.73e-4 |
TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-2 | 1.24e-2 |
TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-3 | 3.34e-2 |
Personality Big5 | Agreeableness | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 1.27e-2 |
Personality Big5 | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 3.76e-2 |
Reproductive Behavior | Number Children Even Born Pooled | MTC | Barban | 2016 | NA | 329139 | 5.00e-2 | 5.08e-3 |
Reproductive Behavior | Number Children Ever Born Female | MTC | Barban | 2016 | NA | 225230 | 5.00e-2 | 7.31e-6 |
Sleep Duration | Oversleeper | MTC | Jones | 2016 | NA | 91306 | 1.00e-2 | 3.13e-3 |
Stroke (ischemic) | All Ischemic Stroke | MTC | Traylor | 2017 | 12389 | 62004 | 5.00e-2 | 2.31e-2 |
Smoking | Current Vs Former Discrete | MTC | Furberg | 2010 | 20619 | 15226 | 5.00e-2 | 1.36e-2 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 1.00e-3 | 4.44e-2 |
Social Deprivation | Household Income | MTC | Hill | 2016 | NA | 112005 | 1.00e-2 | 2.45e-2 |
Social Deprivation | Townsend Score | MTC | Hill | 2016 | NA | 96900 | 5.00e-2 | 8.89e-3 |
Social Deprivation | Townsend Score | MTC | Hill | 2016 | NA | 96900 | 1.00e-4 | 4.37e-2 |
Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 6.60e-3 |
Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.82e-2 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 5.00e-2 | 2.10e-2 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-2 | 4.70e-2 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 3.58e-2 |
Waist Format 1 | Waist Circumference European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 4.24e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 3.91e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 8.14e-3 |
Waist Format 2 | Hip Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 3.38e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 3.66e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 9.93e-3 |
Waist Format 2 | Hip Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 1.74e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 1.80e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 3.05e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 3.14e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 8.14e-3 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 4.47e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 2.31e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 3.17e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-5 | 3.16e-2 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 6.77e-3 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-2 | 4.41e-2 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-3 | 4.63e-3 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-4 | 9.42e-3 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-5 | 4.15e-3 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 2.24e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-2 | 1.35e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 2.49e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-5 | 3.08e-2 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 5.00e-2 | 1.71e-2 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-3 | 5.42e-4 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-5 | 5.63e-3 |
Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 1.00e-2 | 7.26e-3 |
Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 1.00e-3 | 7.93e-3 |
Parkinsons | Parkinsons disease, age of onset | ETC | Blauwendraat | 2019 | NA | 17996 | 1.00e-3 | 3.23e-2 |
Sleep | Diurnal inactivity | ETC | Jones | 2019 | NA | 84757 | 1.00e-5 | 1.55e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.54e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-4 | 4.22e-2 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 5.00e-2 | 5.57e-3 |
K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 5.00e-2 | 4.13e-2 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-2 | 4.71e-2 |
MI/CF | Meconium ileus in cystic fibrosis | ETC | Gong | 2019 | 1115 | 5655 | 5.00e-2 | 3.28e-2 |
MI/CF | Meconium ileus in cystic fibrosis | ETC | Gong | 2019 | 1115 | 5655 | 1.00e-2 | 7.78e-3 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-2 | 4.35e-2 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-2 | 3.38e-2 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 3.29e-2 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 2.80e-2 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-4 | 3.51e-2 |
Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 1.80e-2 |
Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 8.27e-4 |
Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 1.16e-2 |
Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-4 | 6.82e-3 |
Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-2 | 4.68e-3 |
Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 5.00e-2 | 1.05e-3 |
Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 5.00e-2 | 2.82e-2 |
Osteoarthritis | Knee osteoarthritis | ETC | Tachmazidou | 2019 | 24955 | 376169 | 5.00e-2 | 8.90e-3 |
Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 5.00e-2 | 2.50e-4 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-3 | 4.43e-2 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 4.07e-2 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 1.17e-2 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 9.63e-3 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-5 | 3.45e-2 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 3.90e-2 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 9.65e-3 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 9.74e-3 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 8.06e-3 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-4 | 2.38e-2 |
Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 1.97e-2 |
Parasubiculum volume | Parasubiculum volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.11e-2 |
Hippocampal volume | Hippocampal subfield CA4 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.64e-2 |
Hippocampal volume | Hippocampal subfield CA4 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.53e-2 |
Subiculum volume | Subiculum volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 7.01e-3 |
Presubiculum volume | Presubiculum volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.96e-5 |
Presubiculum volume | Presubiculum volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.56e-3 |
Hippocampal volume | Hippocampal subfield CA3 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.53e-2 |
HATA volume | Hippocampal amygdala transition area volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.50e-2 |
Hippocampal volume | Hippocampal subfield CA3 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.17e-2 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 5.00e-2 | 2.89e-3 |
ACR | Urinary albumin to creatinine ratio | ETC | Zanetti | 2019 | NA | 218759 | 5.00e-2 | 2.94e-2 |
Na/C | Urinary sodium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218450 | 5.00e-2 | 1.00e-3 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 1.42e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-2 | 3.90e-2 |
Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 5.00e-2 | 2.02e-2 |
Medication use | Medication use (vasodilators used in cardiac diseases) | ETC | Wu Y | 2019 | 5,546 | 237,113 | 5.00e-2 | 2.16e-3 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 5.00e-2 | 4.39e-2 |
Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 5.00e-2 | 3.35e-2 |
Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 5.00e-2 | 2.41e-2 |
Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 1.00e-2 | 2.55e-2 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 5.00e-2 | 1.71e-2 |
CKD | Chronic kidney disease | ETC | Wuttke M | 2019 | 64,164 | 561,055 | 5.00e-2 | 1.39e-2 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 5.00e-2 | 2.27e-2 |
Renal cell carcinoma | Renal cell carcinoma female | ETC | Laskar RS | 2019 | 1,992 | 3,095 | 1.00e-2 | 7.44e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 4.09e-2 |
Nonalcoholic Liver disease | Liver fibrosis in non-alcoholic fatty acid liver disease | ETC | Namjou B | 2019 | NA | 235 | 5.00e-2 | 2.08e-2 |
Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 5.00e-2 | 1.71e-3 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 5.00e-2 | 2.47e-3 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 9,844 | 20,403 | 1.00e-2 | 1.62e-2 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-2 | 3.30e-2 |
Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 1.24e-2 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 5.00e-2 | 1.24e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 5.00e-2 | 4.71e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 5.00e-2 | 1.29e-3 |
Occipital lobe volume | Occipital lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 4.22e-3 |
Parietal lobe volume | Parietal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 1.82e-2 |
Frontal lobe volume | Frontal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 5.65e-3 |
Frontal lobe volume | Frontal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-2 | 3.96e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-3 | 2.63e-2 |
Birth | Spontaneous preterm birth (preterm birth) | ETC | Liu X | 2019 | 4,775 | 60,148 | 5.00e-2 | 3.69e-3 |
Birth | Spontaneous preterm birth (preterm birth) | ETC | Liu X | 2019 | 4,775 | 60,148 | 1.00e-2 | 3.27e-2 |
Birth | Spontaneous preterm birth (preterm birth) | ETC | Liu X | 2019 | 4,775 | 60,148 | 1.00e-3 | 1.04e-3 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 5.00e-2 | 6.09e-3 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-3 | 2.95e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 2.41e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-5 | 2.91e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 2.56e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-3 | 5.98e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-4 | 1.62e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-2 | 2.77e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 3.76e-4 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 1.60e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 374,756 | 1.00e-5 | 4.69e-2 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 5.00e-2 | 7.07e-3 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 5.00e-2 | 4.63e-5 |
Height | Height variance | ETC | Wang H | 2019 | NA | 347,086 | 5.00e-2 | 1.31e-4 |
Height | Height variance | ETC | Wang H | 2019 | NA | 347,086 | 1.00e-2 | 1.81e-2 |
Birth weight | Birth weight variance | ETC | Wang H | 2019 | NA | 197,758 | 5.00e-2 | 1.77e-2 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-2 | 3.26e-3 |
Uterine fibroids | Uterine fibroids | ETC | Gallagher CS | 2019 | 20,406 | 223,918 | 5.00e-2 | 2.13e-3 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 5.00e-2 | 3.62e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-3 | 4.29e-2 |
BMI by age | BMI at 6 months old | ETC | Helgeland O | 2019 | NA | 8,017 | 5.00e-2 | 5.28e-3 |
Left ventricular | Left ventricular mass | ETC | Aung N | 2019 | NA | 16,920 | 5.00e-2 | 1.16e-2 |
Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 5.00e-2 | 2.41e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 2.10e-3 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 2.83e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-3 | 1.41e-2 |
Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 5.00e-2 | 4.88e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 5.00e-2 | 1.85e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-2 | 1.27e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 5.00e-2 | 1.70e-2 |
Temporale grey matter volume | Right planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,039 | 5.00e-2 | 3.24e-2 |
Temporale grey matter volume | Right planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,039 | 1.00e-3 | 4.70e-2 |
Temporale grey matter volume | Left planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,037 | 5.00e-2 | 9.26e-3 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-2 | 9.66e-3 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-2 | 2.48e-3 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-3 | 7.59e-3 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-4 | 5.76e-3 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-5 | 3.93e-2 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 5.00e-2 | 2.56e-3 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-2 | 1.34e-3 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-3 | 1.09e-2 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-2 | 2.69e-4 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-3 | 3.65e-2 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-4 | 1.95e-2 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.63e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.19e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.06e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 6.26e-3 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.72e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-2 | 2.27e-3 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 1.88e-3 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 4.30e-3 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 2.52e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-5 | 2.96e-2 |
COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 5.00e-2 | 4.68e-2 |
COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 5.00e-2 | 2.26e-2 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis I) | ETC | Ellinghaus D | 2020 | 1610 | 2205 | 5.00e-2 | 6.53e-3 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis I) | ETC | Ellinghaus D | 2020 | 1610 | 2205 | 1.00e-2 | 2.38e-2 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis I) | ETC | Ellinghaus D | 2020 | 1610 | 2205 | 1.00e-3 | 1.35e-3 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis II) | ETC | Ellinghaus D | 2020 | 1610 | 2180 | 5.00e-2 | 3.43e-2 |
COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 1.00e-2 | 3.64e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.